Literature DB >> 25391970

MGMT promoter methylation in non-neoplastic brain.

Chih-Yi Hsu1, Hsiang-Ling Ho, Yi-Chun Chang-Chien, Yi-Wen Chang, Donald Ming-Tak Ho.   

Abstract

O(6)-methylguanine-DNA-methyltransferase (MGMT) is mainly regulated by cytosine-guanine island promoter methylation that is believed to occur only in neoplastic tissue. The present study was undertaken to investigate whether methylation occurs also in non-neoplastic brains by collecting 45 non-neoplastic brains from autopsies and 56 lobectomy specimens from epileptic surgeries. The promoter methylation status of MGMT was studied by methylation-specific polymerase chain reaction (MSP) and pyrosequencing (PSQ), while protein expression was studied by immunohistochemical stain (IHC). The methylation rates, as determined by MSP and PSQ, were 3.0 % (3/101) and 2.9 % (2/69), respectively. Of note, no case had positive result concomitantly from both MSP and PSQ (3 were MSP+/PSQ- and 2 were MSP-/PSQ+), and all the positive samples were further confirmed by cloning and Sanger sequencing. All the methylated cases, except for those having indeterminate IHC results from autopsy specimens, revealed no loss of MGMT protein expression and similar staining pattern to that of the unmethylated cases. In conclusion, the current study demonstrated that MGMT promoter methylation could occur in a low percentage of non-neoplastic brains but did not affect the status of protein expression, which could be regarded as a normal variation in non-neoplastic brains.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25391970     DOI: 10.1007/s11060-014-1663-3

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  32 in total

1.  Determination of the methylation status of MGMT in different regions within glioblastoma multiforme.

Authors:  Mark G Hamilton; Gloria Roldán; Anthony Magliocco; John B McIntyre; Ian Parney; Jacob C Easaw
Journal:  J Neurooncol       Date:  2010-07-21       Impact factor: 4.130

2.  Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C --> A:T mutations of the TP53 tumor suppressor gene.

Authors:  M Nakamura; T Watanabe; Y Yonekawa; P Kleihues; H Ohgaki
Journal:  Carcinogenesis       Date:  2001-10       Impact factor: 4.944

3.  O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.

Authors:  Emmanuèle Lechapt-Zalcman; Guénaëlle Levallet; Audrey Emmanuelle Dugué; Anne Vital; Marie-Danièle Diebold; Philippe Menei; Philippe Colin; Philippe Peruzzy; Evelyne Emery; Myriam Bernaudin; Françoise Chapon; Jean-Sébastien Guillamo
Journal:  Cancer       Date:  2012-02-22       Impact factor: 6.860

4.  Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors.

Authors:  Maria Möllemann; Marietta Wolter; Jörg Felsberg; V Peter Collins; Guido Reifenberger
Journal:  Int J Cancer       Date:  2005-01-20       Impact factor: 7.396

5.  Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis.

Authors:  Thomas Mikeska; Christoph Bock; Osman El-Maarri; Anika Hübner; Denise Ehrentraut; Johannes Schramm; Jörg Felsberg; Philip Kahl; Reinhard Büttner; Torsten Pietsch; Andreas Waha
Journal:  J Mol Diagn       Date:  2007-07       Impact factor: 5.568

6.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

7.  Inducibility of the DNA repair gene encoding O6-methylguanine-DNA methyltransferase in mammalian cells by DNA-damaging treatments.

Authors:  G Fritz; K Tano; S Mitra; B Kaina
Journal:  Mol Cell Biol       Date:  1991-09       Impact factor: 4.272

8.  DNA methylation of multiple promoter-associated CpG islands in meningiomas: relationship with the allelic status at 1p and 22q.

Authors:  M Josefa Bello; Cinthia Amiñoso; Isabel Lopez-Marin; Dolores Arjona; Pilar Gonzalez-Gomez; M Eva Alonso; Jesus Lomas; Jose M de Campos; M Elena Kusak; Jesus Vaquero; Alberto Isla; Manuel Gutierrez; Jose L Sarasa; Juan A Rey
Journal:  Acta Neuropathol       Date:  2004-09-10       Impact factor: 17.088

9.  Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide.

Authors:  Olivier L Chinot; Maryline Barrié; Stephane Fuentes; Nathalie Eudes; Sophie Lancelot; Philippe Metellus; Xavier Muracciole; Diane Braguer; L'Houcine Ouafik; Pierre-Marie Martin; Henry Dufour; Dominique Figarella-Branger
Journal:  J Clin Oncol       Date:  2007-04-20       Impact factor: 44.544

10.  MGMT CpG island is invariably methylated in adult astrocytic and oligodendroglial tumors with IDH1 or IDH2 mutations.

Authors:  Shani Mulholland; Danita M Pearson; Rifat A Hamoudi; Deborah S Malley; Caroline M Smith; Jamie M J Weaver; David T W Jones; Sylvia Kocialkowski; L Magnus Bäcklund; V Peter Collins; Koichi Ichimura
Journal:  Int J Cancer       Date:  2012-01-11       Impact factor: 7.316

View more
  3 in total

1.  The MGMT promoter single-nucleotide polymorphism rs1625649 had prognostic impact on patients with MGMT methylated glioblastoma.

Authors:  Chih-Yi Hsu; Hsiang-Ling Ho; Shih-Chieh Lin; Tiffany Dai-Hwa Ho; Donald Ming-Tak Ho
Journal:  PLoS One       Date:  2017-10-16       Impact factor: 3.240

2.  MGMT-Methylation in Non-Neoplastic Diseases of the Central Nervous System.

Authors:  Sarah Teuber-Hanselmann; Karl Worm; Nicole Macha; Andreas Junker
Journal:  Int J Mol Sci       Date:  2021-04-08       Impact factor: 5.923

3.  MGMT assessment in pituitary adenomas: comparison of different immunohistochemistry fixation chemicals.

Authors:  Alexander S G Micko; Romana Höftberger; Adelheid Wöhrer; Matthias Millesi; Engelbert Knosp; Stefan Wolfsberger
Journal:  Pituitary       Date:  2018-06       Impact factor: 4.107

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.